Search 

Novo Seeds is a life science supporting program launched by the Novo Nordisk Foundation and Novo A/S. Novo Seeds has two components, a pre-seed funding capacity and a seed financing fund. Both aim at identifying and developing the unexplored commercial potential present in academic and early stage applied research projects at universities and biotech companies within life science in Scandinavia.

The pre-seed program supports early stage projects based on ideas and results with commercial potential. Funding is given as grants in the same manner as other grants awarded by the Novo Nordisk Foundation.

The seed fund aims at supporting more advanced projects and will operate on commercial terms, i.e. support is given to projects and companies in exchange for ownership or other rights to the companies/projects. Typically, the seed program will invest in newly formed companies that are too early in their development stage to be supported by Novo A/S’ venture capital or other international investors

Otivio is a Medtech company with technology which improves blood flow to the limbs of patients. This can be used for treatment of chronic ischemic wounds, in particular for patients with reduced peripheral circulation.

Another application is to exploit the improved blood flow to heat or cool patients by using the the limb as a heat exchanger.

Otivio is a coordinator of an EU funded project and are currently looking for funding to strenghten its organization and fund additional activites.

RemoteA Ltd offers easy-to-use and cost-efficient solutions for simplifying the diagnosis of common medical disorders like cardiac arrhythmias, sleep apnea and hypertension.

Firstly, our browser-based system with state-of-the-art data security enables medical specialist consultation in the first point of care. Health care costs will be substantially reduced as fewer patients will be referred to hospitals; instead they can be diagnosed and treated in the first point of care. Simultaneously, accessibility to care and quality of care are improved.

Secondly, our smart ECG solution enables cardiac arrhythmias testing at home analogically to how blood pressure measurements were shifted from doctors' offices to homes in 1980’s and 1990’s.

Technology is based on the development since 2002.